RxDoctor Payments Data

Eric Kroner, PA

Physician Assistant · State College, PANPI 1730149998

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 46 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$164
  • Globus Medical$148
  • Gilead$131
  • AbbVie$129
  • Neurelis, Inc.$124
  • AstraZeneca$78
  • plus $697 from 22 others

What the payments were for

  • Consulting fees$252%
  • Food & beverage$1,44598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$16,004
Medicare patients
106
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,875
EliquisApixaban12$10,129
Prochlorperazine Maleate121$3,853
Roflumilast16$1,349
Ondansetron OdtOndansetron50$580
Dexamethasone49$548
Albuterol Sulfate HfaAlbuterol Sulfate20$508
Oxycodone Hcl25$344
Montelukast Sodium11$317
Potassium Chloride13$174
Olanzapine18$119
Letrozole16$86
Prednisone17$84
Levofloxacin18$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$47$21,87526 claims
PfizerEliquis$21$10,12912 claims
Lilly USA, LLCOlanzapine$22$11918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →